Research and Markets: The Largest Deal Announced in the Third Quarter Was the $7.4 Billion Acquisition of Ivax By the Israel-Based Generics Giant, Teva Pharmaceuticals
Posted on: Friday, 31 March 2006, 09:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c32223) has announced the addition of Life Sciences Industry: Quarterly Deal Review -Third Quarter to their offering.
According to this Decision Resources report, biotechnology continued its steady rebound in the third quarter, pacing an overall strong quarter for the life sciences. The AMEX Biotechnology index posted a 14.9% gain during the quarter, easily beating the 2.9% and 4.6% gains posted by the DOW and NASDAQ exchanges, respectively. Taking their cue from the bullish marketplace, life sciences companies began once again to issue initial public offerings (IPOs); six U.S. life sciences companies made IPOs in the third quarter, up from only two in the second quarter. Secondary public offerings (SPOs) also benefited from the renewed climate of investor confidence; a total of 25 SPOs were made in the third quarter, helping the industry raise $1.4 billion.
Alliance activity dropped dramatically in the third quarter: a total of 296 deals were struck by the industry in the third quarter, down from 402 and 471 in the second and first quarters, respectively. Ownership changes witnessed a similar drop in activity in the third quarter. The industry recorded 74 ownership changes in the third quarter, down from 94 in the previous quarter. The largest deal announced in the third quarter was the $7.4 billion acquisition of Ivax by the Israel-based generics giant, Teva Pharmaceuticals. In this report, the author reviews select IPOs, SPOs, debt financings, private placement and venture capital activity, ownership changes, and company alliances. This Decision Resources report also examines the third quarter's most active pharmaceutical and biotech companies.
Topics covered in this report include:
-- Overview
-- Financings
-- Initial Public Offerings
-- Secondary Public Offerings
-- Debt Financings
-- Private Placements and Venture Capital
-- Ownership Changes
-- Alliances
-- Most Active Pharmaceutical Companies
-- Most Active Biotechnology Companies
For more information visit http://www.researchandmarkets.com/reports/c32223
Source: Business Wire
Related Articles
- Red Cross Announces 'Change a Life' Contest Winners
- Coverity(R) Reports Largest Quarter in Company History as Customer Base Surpasses 600
- Insurance Industry Offers Lower Cost For Sick People
- Examine the Europe Aviation Sectors With This Updated Company and Industry Analysis (May 2008)
- Examine the North American Food & Beverage Sectors: A Company and Industry Analysis (June 2008)
- Examine the North American Healthcare Sectors: A Company and Industry Analysis (July 2008)
- Research and Markets: North America Pharmaceuticals Sectors: A Company and Industry Analysis (July 2008) - in 2007, Total Drugs Spending in Canada Totalled C$27 Billion (US$26.75 Billion)
- North America Mining Sectors: A Company and Industry Analysis (June 2008) - Prices For Primary Metal Products in Canada Rose 9.2% in the First Quarter Of 2008
- A Company and Industry Analysis of the European Pharmaceutical Sectors Providing the Latest Data on the Current Environment & Market Trends
- Gerdau Ameristeel to Present at the JPMorgan Third Annual Basics & Industrials Conference
 |
 |
User Comments (0)
RSS Feeds